Serological responses to COVID-19 booster vaccine in England

Introduction

Two doses of BNT162b2 (Pfizer-BioNTech/Comirnaty^®) or AZD1222 (AstraZeneca/Vaxzevria^®) vaccines provide high levels of protection from COVID-19, hospitalisation and death for at least 4-6 months after vaccination.¹ Unlike other countries that that offered COVID-19 vaccination according to the authorised 3-4 week interval, the UK recommended an extended 12-week schedule to expedite the rollout of the first dose of vaccine.¹ Subsequent studies have demonstrated higher antibody levels after the second dose with the extended schedule than the authorised interval, potentially providing better longer-term protection.^1,2 However, antibody levels and clinical protection wane over time. In England, vaccine effectiveness (VE) against hospitalisation declined to 77.0% and 92.7% beyond 20 weeks post-vaccination and 78.7% and 90.4% against death for AZD1222 and BNT162b2, respectively, with greater waning among older adults and those with underlying comorbidities.² As these groups were the first to be offered COVID-19 vaccination and because of concerns about waning immunity, emergence of the highly-transmissible Delta variant which causes more severe disease and can infect vaccinated individuals,^3,4 high and sustained community infection rates in the UK, and winter pressures on the national healthcare system, the UK Joint Committee on Vaccination and Immunisation (JCVI) recommended a third dose (booster) with either a single dose of BNT162b2 or a half dose (50µg) of mRNA-1273 (Moderna/Spikevax^®) for adults aged ≥50 years, individuals aged 16-49 years in clinical risk groups, adult carers and household contacts of immunosuppressed individuals, and frontline health and social care workers, to be offered at least 6 months after their second dose.^5-7

In England, the UK Health Security Agency (UKHSA) initiated an evaluation of vaccine responses in adults aged ≥50 years who received the BNT162b2 or AZD1222 as part of the national immunisation programme to compare short versus longer interval vaccine schedules and monitor antibody waning over time.⁸ Here, we describe the antibody kinetics after primary immunisation and booster vaccination in adults aged ≥50 years who were vaccinated as of the national COVID-19 immunisation programme.

Methods

The COVID-19 vaccine responses after extended immunisation schedules (CONSENUS) cohort has been described previously.^1,8 CONSENSUS recruited immunocompetent adults aged >50 years in January 2021 in London to provide serial blood samples at 0,3,6,9,12,15 and 20 weeks after their first dose of COVID-19 vaccine. As part of the national COVID-19 vaccine roll out, participants received either (i) two BNT162b2 doses <30 days apart (BNT162b2-control), (ii) two BNT162b2 doses ≥30 days apart (BNT162b2-extended) or (iii) two AZD1222 doses ≥30 days apart (AZD1222-extended). Additional blood samples were taken before and after the booster.

Serum samples were tested for nucleoprotein (N) antibodies as a marker of previous SARS-CoV-2 infection (Elecsys Anti-SARS-CoV-2 total antibody assay, Roche Diagnostics, Basel, Switzerland: positive ≥1 COI) and spike (S) protein antibodies, which could be infection-or vaccine-derived (Elecsys Anti-SARS-CoV-2 S total antibody assay, Roche Diagnostics: positive⍰≥⍰0.8 arbitrary units (au)/mL to assess vaccine response). Antibody geometric mean titres (GMTs) were calculated with 95% confidence intervals (CI). Geometric mean ratios (GMR) of responses between timepoints were estimated using a mixed regression model on log responses including a random effect for each participant; separate models were fitted for each vaccine group. The GMR of responses by vaccine type at each post-vaccination timepoint was estimated via regression on log Roche S responses and included age-group and sex. Statistical analyses were performed using STATA v.14.2. Individuals with ≥0.4 (au)/mL on the Roche N assay were considered to have had prior SARS-CoV-2 infection.

Results

Discussion

These early data show a rapid serological response to boosting with BNT162b2, with significantly higher antibody responses than after the second dose. Importantly, our cohort consists primarily of older adults who have a higher risk of severe COVID-19 and are, therefore, most likely to benefit from vaccination. Early data from Israel and England demonstrate significantly better protection against severe COVID-19, hospitalisation and death after booster vaccination.^2,9 In England, 14 days after boosting with BNT162b2 among ≥50 year-olds, VE was similar in individuals who had received only 2 primary doses of BNT162b2 (87.4, 95%CI 84.9-89.4) and AZD1222 (84.4, 95%CI 82.8-85.8) at least 140 days previously, although the analysis did not separate by schedule.² The higher post-booster GMTs in BNT162b2-control participants, who were the first to be vaccinated, is likely due to the extended interval between primary and booster vaccines, allowing more time for enhancing immune memory and greater waning of antibodies, both of which are likely to enhance post-booster responses.

In conclusion, we observed very high antibody responses following a BNT162b2 booster, irrespective of vaccine or schedule used for primary immunisation. A longer interval between primary immunisation and the booster provides higher post-booster antibody responses and, potentially, longer lasting protection. Decisions on timing of booster doses should take account of the current and predicted epidemiological context to ensure the most vulnerable groups are optimally protected during heightened periods of transmission. Whilst the rates of severe disease, hospitalisations and deaths remain low in individuals receiving primary immunisation only, the booster programme will provide additional protection to those at highest risk of severe COVID-19 and help reduce infection rates across the population.¹⁰ Ongoing surveillance will be important for monitoring duration of protection offered by booster doses and any need for additional doses in the future.

Funding

This surveillance was funded by Public Health England (PHE) (now UK Health Security Agency[UKHSA]). The CONSENSUS study/audit was approved by the PHE R&D Research Ethics and Governance Group. No: NR0253

Data availability

Applications for relevant anonymised data should be submitted to the UK Health Security Agency Office for Data Release.

Author Contributions

SL, FB, PM, MR, KB, GA conceived and designed the study; LW and EL supervised the laboratory testing; SS, CW, MO’B and FB co-ordinated the patient enrolment. HW performed the statistical analysis and GI, GA, SL, and KB wrote the manuscript. All authors read and approved the submission.